Shots:
- The P-II study involves assessing the efficacy, safety and PK of Iptacopan (LNP023) in patients with C3G (Cohort A) and patients who have undergone a kidney transplant and have C3G recurrence (Cohort B), interim results presented at ASN 2020
- Result: @12wks., reduction in proteinuria (49%) as measured by 24hrs. UPCR assessment; improvement in plasma C3 level; inhibit alternative complement pathway activity; stabilized renal function as assessed by eGFR
- Iptacopan (PO) is a first-in-class reversible inhibitor of factor B and has received EMA’s PRIME designation for iptacopan in C3G and EMA’s ODD in IgAN. The therapy is in development for multiple renal conditions including C3G, IgAN, aHUS, iMN as well as in PNH which is a hematological disease
Click here to read full press release/ article | Ref: Novartis | Image: Whistleblower News Review
The post Novartis Presents Results of Iptacopan (LNP023) in P-ll Study for C3 Glomerulopathy at ASN Annual Meeting 2020 first appeared on PharmaShots.
